Bivatuzumab mertansine
Appearance
This article relies largely or entirely on a single source. (August 2014) |
![]() | |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | CD44 v6 |
Clinical data | |
ATC code |
|
Identifiers | |
ChemSpider |
|
![]() ![]() |
Bivatuzumab mertansine is a combination of bivatuzumab, a humanized monoclonal antibody, and mertansine, a cytotoxic agent. It is designed for the treatment of squamous cell carcinoma.[1]
References
- ^ Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, et al. (October 2006). "A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus". Clinical Cancer Research. 12 (20 Pt 1): 6064–72. doi:10.1158/1078-0432.CCR-06-0910. PMID 17062682.